AAV Neutralizing Antibody Assay for Personalized Vector Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Humoral immunity against adeno-associated virus (AAV) vectors, particularly neutralizing antibodies (NAbs), poses a significant barrier to intravascular gene transfer due to widespread capsid protein sequence homology, leading to vector clearance before reaching target cells, and there is limited understanding of Nab levels in synovial fluid and their relationship with serum levels.
Innovation Solution
Development of recombinant AAV vectors with a reporter transgene, operably linked to expression regulatory elements and flanked by flanking elements, for in vitro analysis of antibody binding, allowing personalized vector selection based on antibody presence and titer in subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV vectors are introduced into the bloodstream for intravascular gene transfer, then gene delivery to target tissues is achieved, but neutralizing antibodies clear the vector before it reaches target cells
Solution Approach 1:
The patent performs preliminary assessment of neutralizing antibody levels in subjects before gene transfer therapy. By measuring anti-AAV antibody titers in serum and synovial fluid beforehand, the system identifies subjects who are suitable candidates for intravascular AAV vector administration, thereby preventing vector clearance by pre-existing neutralizing antibodies
Solution Approach 2:
The patent uses reporter transgene expression as an intermediary indicator to assess vector neutralization. By measuring reporter gene expression levels after controlled vector administration, the system indirectly quantifies neutralizing antibody activity without directly measuring antibody- vector interactions
2Measurement precision
If neutralizing antibody levels are measured to prevent vector clearance, then gene transfer efficacy is improved, but limited understanding of Nab levels in synovial fluid vs serum hinders accurate assessment
Solution Approach 1:
The patent develops a universal assay system that can measure neutralizing antibody levels in multiple body fluids including both serum and synovial fluid using the same methodological approach. This multi-fluid assessment capability provides comprehensive information about the subject's immune status against AAV vectors
Solution Approach 2:
The patent compares neutralizing antibody titers across different body fluids (serum vs synovial fluid) to understand the relationship between compartments. By measuring and comparing antibody levels in these different locations, the system gains insight into the distribution and neutralization potential in various tissue environments
3Productivity
If high doses of AAV2 vector are administered to overcome neutralizing antibodies, then gene transfer may be achieved, but subjects express moderate or substantial amounts of antibody against AAV2
Solution Approach 1:
The patent converts the harmful effect of pre-existing neutralizing antibodies into a beneficial diagnostic tool. By measuring these antibodies' neutralization of reporter transgene expression, the system uses them to identify suitable subjects and select appropriate vector serotypes, turning the immune barrier into a screening mechanism for personalized therapy
Data Source
AI summary
Virus vectors, virus particles, and methods and uses of screening for, detecting, analyzing and determining amounts of virus antibody, or neutralizing antibody activity of samples are provided. Such virus vectors, virus particles, and methods and uses are applicable to a broad range of virus types, such as lentiviruses, adenovirus, and adeno-associated virus (AAV) serotypes. Methods and uses include virus antibody screening, such as anti-virus immunoglobulins screened for, detected, analyzed and amounts determined.